ICER Releases Two Draft Reports on Obeticholic Acid

The Institute for Clinical and Economic Review (ICER) recently released two Draft Evidence Reports assessing the comparative clinical effectiveness and value of obeticholic acid. Learn more about its use for primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH) here. (Source: ICER, 5/25/16)

You might also be interested in:

Amalgam Rx™ and AWS Collaborate to Accelerate and Simplify… 07/19/2021
The Journal of Clinical Pathways Issues Call for Papers 04/16/2021
IQVIA Collaborates with HealthCore to Advance Clinical… 09/08/2021
ICER Meets With FDA, EMA, and FDA to Discuss RWE Procedures 10/12/2021
New Podcast Featuring ICER President on Consequences of High… 04/27/2021
Syntropy and UCI Unite in 5-Year RWD Collaboration to Improve… 10/13/2021
ICER Analytics™ Accelerates Real-World Application of ICER Reports 12/04/2020